These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30980209)

  • 41. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology].
    Pivot X; Goupille P
    Med Sci (Paris); 2019 Dec; 35(12):1137-1145. PubMed ID: 31903928
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients.
    Papautsky EL; Carlson M; Johnson SM; Montague H; Attai DJ; Lustberg MB
    Breast Cancer Res Treat; 2022 Jul; 194(1):25-33. PubMed ID: 35568748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evolution of biosimilars in oncology, with a focus on trastuzumab.
    Nixon NA; Hannouf MB; Verma S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S171-S179. PubMed ID: 29910660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
    Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
    JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biosimilars for breast cancer.
    Migliavacca Zucchetti B; Nicolò E; Curigliano G
    Expert Opin Biol Ther; 2019 Oct; 19(10):1015-1021. PubMed ID: 31248290
    [No Abstract]   [Full Text] [Related]  

  • 49. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Switching to biosimilars in the treatment of rheumatic diseases.
    Yoo DH; Choe JY; Shim SC; Suh CH
    Expert Rev Clin Immunol; 2018 Jul; 14(7):557-571. PubMed ID: 29914272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can we establish a hierarchy among trastuzumab biosimilar candidates?
    Pivot X; Petit T
    Br J Cancer; 2018 Aug; 119(3):263-265. PubMed ID: 30002436
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
    Serna-Gallegos TR; La-Fargue CJ; Tewari KS
    Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
    Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trial Validates Biosimilar for Trastuzumab.
    Cancer Discov; 2016 Jul; 6(7):686-7. PubMed ID: 27277256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
    Cazap E; Jacobs I; McBride A; Popovian R; Sikora K
    Oncologist; 2018 Oct; 23(10):1188-1198. PubMed ID: 29769386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share.
    Chen AJ; Kaiser KM; Gascue L; Manetas MA; Van Nuys K
    Health Aff (Millwood); 2023 Jun; 42(6):779-784. PubMed ID: 37276475
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The global landscape of drug development of trastuzumab biosimilars.
    Trapani D; Curigliano G
    J Cancer Policy; 2021 Jun; 28():100273. PubMed ID: 35559916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biosimilar medicines used for cancer therapy in Europe: a review.
    Santos SB; Sousa Lobo JM; Silva AC
    Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023.
    Wu Q; Wang Z; Fu Y; Luo R; Sun J
    Glob Health Res Policy; 2024 Oct; 9(1):42. PubMed ID: 39367503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.